Innovating Future Medicine with mRNA Technology
SML Biopharm Co., Ltd. is a company specializing in mRNA-based vaccine and therapeutic development, established in 2021 through Professor Jae-Hwan Nam's university startup at Catholic University of Korea.
Experts with over 10 years of research experience in mRNA vaccines and immunoadjuvants have gathered to provide new treatment opportunities for patients suffering from diseases without treatments through differentiated mRNA platform technology.
Vision
Growing into a globally competitive biotech company utilizing mRNA technology, contributing to a healthy future for humanity.
Mission
Developing innovative therapeutics for various diseases with differentiated mRNA platform technology, providing new hope to patients suffering from untreatable diseases.
An Innovative Journey for the Future
Jae-Hwan Nam
CEO, SML Biopharm Co., Ltd.
History
Check out the growth history of SML Biopharm.
Government Grant Selected (KDCA)
Support Program for Developing mRNA Vaccines in Preparation for a Pandemic
Selection of Chungbuk Advanced Regenerative Bio Global Innovation Special Zone Project Operator
Chungcheongbuk-do, Republic of Korea
Government Grant Selected (Ministry of Health and Welfare)
Development of mRNA-Based Antibody Therapeutics for Severe Fever with Thrombocytopenia Syndrome (SFTS)
Opening of a branch office in Cheongju, Chungcheongbuk-do
Government Grant Selected (KDCA)
Preclinical Sample Production and Evaluation for Securing SFTS therapeutic candidate substance
Grant Selected Top 1000+ Next-Generation Startups
(Ministry of SMEs and Startups)
Government Grant Selected (KDCA)
SFTS Immune Candidate Non-clinical and Sample Production Condition Establishment
New headquarter and In-House Research Center Established at M Cluster by Gwangmyeong Station
Series A Funding from Meritz Securities Secured
Venture Business Status Certified
Company - Affiliated Research Laboratory Established at Catholic University of Korea
Seed Funding from Samkwang Labtree Co. Ltd. Secured
SML Biopharm Established
(Faculty Startup in the Department of Biomedical Sciences at Catholic University of Korea)
Strategic Partnerships
We collaborate with leading institutions worldwide to develop innovative therapeutics.
Probio
ChinamRNA Development, Manufacturing & Clinical Research Collaboration
CATUG
SwitzerlandmRNA Technology Development & Commercialization Collaboration
Affilogic
FranceNanofitin-based Targeted Drug Development
Cha Vaccine Institute
South KoreamRNA-based Vaccine & Therapeutics Co-development
Catholic University of Korea
South KoreaIndustry-Academia Cooperation & CUK-SML Biomedical Center Operation
KDCA
South KoreaSFTS Therapeutic Candidate Development Project
MOHW
South KoreaInfectious Disease Prevention & Treatment Technology Development
